Fig. 4.

Kinome alteration following 2 weeks of treatment with buparlisib, selumetinib, or combination in intracranial SUM149 TNBC tumors. (A) Fold change of kinases comparing buparlisib (green), selumetinib (blue), or combination (red) relative to controls. Only kinases with a Log2 fold change of >0.5 or <−0.5 in any treatment group relative to controls are shown. B‒D. Kinome tree diagrams of altered kinases following (B) buparlisib, (C) selumetinib, and (D) combination, colored by fold change relative to controls: ≥2x (red), 1.5x–2x (pink), ≤0.5x (blue), unchanged (black), detected only in treatment (gray).